Calidi Biotherapeutics Inc (CLDI) Stock Price, Quote & News

Company Profile

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 794 9600

Fax: 858 794 9605

Website: www.calidibio.com

Address:

4475 Executive Drive, Suite 200, San Diego, United States

Olivia_Strickland Jun. 29 at 8:08 AM

$CLDI poking up 10% premarket on a sub-20 cent name, 1.8M shares through it already. these thin gappers love to fade the whole move once the bell rings. what's the read here, anyone got eyes on it? added to my open list: https://tapeboard.com/go/st/scanner?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=cldi-pm-up-watch&utm_term=scanner&s=CLDI

0 · Reply

QQQ_Guy Jun. 29 at 12:08 AM

$CLDI tomorrow is a big day, possible buyout! It’s time to get rich boys!

1 · Reply

NolAsrtormZ Jun. 28 at 7:49 PM

$CLDI .... see @race2zero is now focused on $GRI which has more then .16cents to miss. Your welcome @race2zero

0 · Reply

NolAsrtormZ Jun. 28 at 5:40 PM

$CLDI .... @race2zero you ever looked at gri bio? Its pretty disturbing how r/s they have done. Its a "ipf drug" co lolololol it almost well ill let you research it. There is so much more 2 go

1 · Reply

race2zero Jun. 28 at 5:32 AM

$CLDI @Banana3 where did you go? Remember when you tried to talk shit and how big you were…that was funny, now you just disappeared like the insignificant little coward you are 🤣🤣🤣🤣

0 · Reply

QQQ_Guy Jun. 27 at 5:30 AM

$CLDI back to .21 there is a lot of value here. This stock is a hidden gem that has not made it known on wallstreet yet.

0 · Reply

race2zero Jun. 27 at 2:44 AM

$CLDI @Banana3

0 · Reply

race2zero Jun. 26 at 9:11 PM

$CLDI @Sabby_Management don’t you love it when these guys @Banana3 come in here and quickly leave with the walk of shame! We own this POS!

1 · Reply

race2zero Jun. 26 at 7:51 PM

$CLDI @Banana3 someone got awfully quiet

0 · Reply

race2zero Jun. 26 at 6:57 PM

$CLDI $MU $SPY $WEN

1 · Reply

Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit

Jun 23, 2026, 8:00 AM EDT - 5 days ago

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

2026-06-16T12:39:20.000Z - 12 days ago

Calidi receives pre-IND regulatory feedback from FDA for CLD-401

Jun 16, 2026, 8:00 AM EDT - 12 days ago

Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study

Jun 8, 2026, 8:00 AM EDT - 20 days ago

Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026

2026-05-26T15:37:20.000Z - 4 weeks ago

Calidi announces online abstract acceptances at 2026 ASCO Meeting

May 26, 2026, 8:00 AM EDT - 4 weeks ago

Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting

2026-05-22T22:05:57.000Z - 5 weeks ago

Calidi provides required NYSE American disclosure

May 22, 2026, 6:00 PM EDT - 5 weeks ago

Calidi Biotherapeutics Provides Required NYSE American Disclosure

May 14, 2026, 4:10 PM EDT - 6 weeks ago

Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights

May 13, 2026, 8:00 AM EDT - 6 weeks ago

Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI

2026-04-21T13:29:48.000Z - 2 months ago

Calidi presents new data on CLD-401 at AACR

2026-04-20T12:54:38.000Z - 2 months ago

Calidi presents new data on in situ t-cell engagers at AACR

Apr 20, 2026, 8:00 AM EDT - 2 months ago

Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

Mar 27, 2026, 4:25 PM EDT - 3 months ago

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights

2026-03-12T12:17:48.000Z - 3 months ago

Calidi presents manufacturing process for CDI-401 at BioProcessing Summit

Mar 12, 2026, 8:00 AM EDT - 3 months ago

Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing

Mar 9, 2026, 8:50 PM EDT - 3 months ago

Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option

2026-03-06T13:35:48.000Z - 4 months ago

Calidi prices 10.5M units at 50c in underwritten public offering

Mar 6, 2026, 8:30 AM EST - 4 months ago

Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering

2026-03-05T23:00:46.000Z - 4 months ago

Calidi announces offering of units, no amount given

Mar 5, 2026, 5:57 PM EST - 4 months ago

Calidi Biotherapeutics Announces Proposed Public Offering

2026-02-20T13:11:19.000Z - 4 months ago

Calidi presents data on novel approach to use of BiTEs

Feb 20, 2026, 8:00 AM EST - 4 months ago

Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference

2026-02-12T13:10:13.000Z - 4 months ago

Calidi to present on approach to bispecific T-cell engagers using RedTail

Feb 12, 2026, 8:00 AM EST - 4 months ago

Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference

2026-01-28T13:13:01.000Z - 5 months ago

Calidi announces 2026 milestones

Nov 17, 2025, 8:00 AM EST - 7 months ago

Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025

Nov 13, 2025, 4:15 PM EST - 8 months ago

Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights

2025-11-10T13:20:35.000Z - 8 months ago

Calidi presents new data on CLD-401 at 2025 SITC annual meeting

2025-10-30T12:15:32.000Z - 8 months ago

Calidi announces new data to be presented on CLD-401 at 2025 SITC meeting

2025-10-22T12:11:42.000Z - 8 months ago

Calidi announces formation of its Scientific Advisory Board

Aug 21, 2025, 6:33 PM EDT - 11 months ago

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option

2025-08-20T13:20:27.000Z - 11 months ago

Calidi prices 1.47M units at $2.00 in underwritten public offering

Aug 20, 2025, 9:15 AM EDT - 11 months ago

Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering

Aug 8, 2025, 4:15 PM EDT - 11 months ago

Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

2025-08-05T13:46:30.000Z - 11 months ago

Calidi Biotherapeutics Inc trading resumes

2025-08-05T13:43:07.000Z - 11 months ago

Calidi Biotherapeutics Inc trading halted, volatility trading pause

2025-07-29T12:22:15.000Z - 11 months ago

Calidi receives FDA Fast Track designation for CLD-201

Jul 25, 2025, 4:45 PM EDT - 1 year ago

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

Jul 22, 2025, 8:00 AM EDT - 1 year ago

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24

Jul 10, 2025, 8:30 AM EDT - 1 year ago

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment

Jul 9, 2025, 2:01 PM EDT - 1 year ago

Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds

Jul 8, 2025, 8:30 AM EDT - 1 year ago

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment

Jun 27, 2025, 8:00 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Shareholder Letter from CEO

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

Apr 16, 2025, 9:30 AM EDT - 1 year ago

Global X Offers Precise U.S. Equity Exposure with Launch of Domestic Focused Funds

EGLE

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Mar 28, 2025, 9:00 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform

Feb 28, 2025, 9:00 AM EST - 1 year ago

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OSTX

Feb 24, 2025, 8:00 AM EST - 1 year ago

Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital

Jan 29, 2025, 8:00 AM EST - 1 year ago

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5

Jan 28, 2025, 8:00 AM EST - 1 year ago

Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement

Jan 10, 2025, 4:30 PM EST - 1 year ago

Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

Jan 10, 2025, 8:30 AM EST - 1 year ago

Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock

Nov 15, 2024, 4:05 PM EST - 1 year ago

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

Nov 14, 2024, 8:30 AM EST - 1 year ago

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

Nov 12, 2024, 5:29 PM EST - 1 year ago

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

Oct 25, 2024, 9:00 AM EDT - 1 year ago

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NXL

Oct 24, 2024, 8:30 AM EDT - 1 year ago

Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences

Oct 23, 2024, 8:31 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

Oct 18, 2024, 11:00 PM EDT - 1 year ago

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)

Oct 18, 2024, 8:45 AM EDT - 1 year ago

Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GRRR

Olivia_Strickland Jun. 29 at 8:08 AM

0 · Reply

QQQ_Guy Jun. 29 at 12:08 AM

$CLDI tomorrow is a big day, possible buyout! It’s time to get rich boys!

1 · Reply

NolAsrtormZ Jun. 28 at 7:49 PM

$CLDI .... see @race2zero is now focused on $GRI which has more then .16cents to miss. Your welcome @race2zero

0 · Reply

NolAsrtormZ Jun. 28 at 5:40 PM

$CLDI .... @race2zero you ever looked at gri bio? Its pretty disturbing how r/s they have done. Its a "ipf drug" co lolololol it almost well ill let you research it. There is so much more 2 go

1 · Reply

race2zero Jun. 28 at 5:32 AM

$CLDI @Banana3 where did you go? Remember when you tried to talk shit and how big you were…that was funny, now you just disappeared like the insignificant little coward you are 🤣🤣🤣🤣

0 · Reply

QQQ_Guy Jun. 27 at 5:30 AM

$CLDI back to .21 there is a lot of value here. This stock is a hidden gem that has not made it known on wallstreet yet.

0 · Reply

race2zero Jun. 27 at 2:44 AM

$CLDI @Banana3

0 · Reply

race2zero Jun. 26 at 9:11 PM

$CLDI @Sabby_Management don’t you love it when these guys @Banana3 come in here and quickly leave with the walk of shame! We own this POS!

1 · Reply

race2zero Jun. 26 at 7:51 PM

$CLDI @Banana3 someone got awfully quiet

0 · Reply

race2zero Jun. 26 at 6:57 PM

$CLDI $MU $SPY $WEN

1 · Reply

uindicator Jun. 26 at 6:41 PM

$CLDI $MU $SPY $WEN Ya thats what you said last time before it went down 90%

0 · Reply

race2zero Jun. 26 at 6:34 PM

$CLDI @Banana3

1 · Reply

Banana3 Jun. 26 at 6:31 PM

$CLDI $WEN $SPY $MU CLDI short squeeze Look at the volume. It’s gonna explode 👀 Not financial advice!

1 · Reply

QQQ_Guy Jun. 26 at 6:21 PM

$CLDI I called the spike yesterday. This is a buy, bulls lets squeeze these shorts. This is a low floater that could go to 99 dollars with volume. I am already getting rich from my cheap shares.

0 · Reply

ka1954 Jun. 26 at 6:17 PM

$CLDI good joke. i will take .25 cents or so at this point

1 · Reply

shuffle13 Jun. 26 at 6:15 PM

$CLDI ideas....effect coming any day now

0 · Reply

Banana3 Jun. 26 at 6:06 PM

$CLDI $SPY $QQQ Look at the volume in $CLDI 👀

1 · Reply

Droidhustler Jun. 26 at 5:58 PM

$CLDI gimmie 1 dolla 🚀

0 · Reply

race2zero Jun. 26 at 5:49 PM

$CLDI and it’s over…..

1 · Reply

Banana3 Jun. 26 at 5:44 PM

$CLDI $IBRX $WEN $CAPR CLDI Volume exploding above VWAP 👀 200 day moving average at $0.80 cents 🤔 Not financial advice!

1 · Reply

i_like_bb_stock Jun. 26 at 5:39 PM

$CLDI took some this guy has a lot of followers first time Ive seen him like a penny stock https://x.com/Banana3Stocks/status/2070554196957647085?s=20

0 · Reply

Kingph31 Jun. 26 at 5:36 PM

$CLDI 🔥

0 · Reply

Market Cap	3.15M
Revenue (ttm)	0.00
Net Income (ttm)	-19.91M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.12

Volume	17,744,900
Avg Vol	6,842,474
Day's Range	N/A - N/A
Shares Out	19.31M
Stochastic %K	44%
Beta	1.31
Analysts	Strong Buy
Price Target	$10.00